Palbociclib
Reading tools
Palbociclib (Ibrance®), which received FDA approval on 3 February 2015, is used after menopause in hormone receptor-positive (ER) and HER2-positive advanced breast cancer patients.
Palbociclib prevents tumor growth and proliferation by inhibiting the functioning of elements such as CDK (cyclin-dependent kinase), necessary during cancer cell division/proliferation. Its side effects include reducing neutrophils, a component of the immune system, fatigue, anemia and nausea.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.